Hong Kong Stocks Move | CARSGEN-B (02171) Surges Over 9% in Early Trading as Company Presents Zewokilanse Injection Research at ESMO 2025

Stock News

Oct 20

CARSGEN-B (02171) experienced a surge of over 9% in early trading, reaching a gain of 9.49% to HKD 17.66, with a trading volume of HKD 11.95 million. The company announced that the research results for Zewokilanse injection (Product ID: CT053), an autologous CAR-T cell product targeting BCMA, were presented in a poster session at the 2025 European Society for Medical Oncology (ESMO) annual meeting. This clinical trial represents the world's first proof-of-concept study investigating CAR-T cell therapy for adjuvant treatment in solid tumors, specifically for pancreatic cancer (PC). Notably, on September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the innovative drug directory for commercial insurance. It is reported that all five CAR-T drugs, including CARSGEN-B's Zewokilanse, passed expert review and are expected to be included in this year's basic medical insurance directory and the commercial insurance innovative drug directory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1101078272"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1101078272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1101078272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101078272","market":"sg","top_or_hot":-1,"title":"Hong Kong Stocks Move | CARSGEN-B (02171) Surges Over 9% in Early Trading as Company Presents Zewokilanse Injection Research at ESMO 2025","media":"Stock News","content":"<p>CARSGEN-B (02171) experienced a surge of over 9% in early trading, reaching a gain of 9.49% to HKD 17.66, with a trading volume of HKD 11.95 million. The company announced that the research results for Zewokilanse injection (Product ID: CT053), an autologous CAR-T cell product targeting BCMA, were presented in a poster session at the 2025 European Society for Medical Oncology (ESMO) annual meeting. This clinical trial represents the world's first proof-of-concept study investigating CAR-T cell therapy for adjuvant treatment in solid tumors, specifically for pancreatic cancer (PC). Notably, on September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the innovative drug directory for commercial insurance. It is reported that all five CAR-T drugs, including CARSGEN-B's Zewokilanse, passed expert review and are expected to be included in this year's basic medical insurance directory and the commercial insurance innovative drug directory.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stocks Move | CARSGEN-B (02171) Surges Over 9% in Early Trading as Company Presents Zewokilanse Injection Research at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stocks Move | CARSGEN-B (02171) Surges Over 9% in Early Trading as Company Presents Zewokilanse Injection Research at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-20 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) experienced a surge of over 9% in early trading, reaching a gain of 9.49% to HKD 17.66, with a trading volume of HKD 11.95 million. The company announced that the research results for Zewokilanse injection (Product ID: CT053), an autologous CAR-T cell product targeting BCMA, were presented in a poster session at the 2025 European Society for Medical Oncology (ESMO) annual meeting. This clinical trial represents the world's first proof-of-concept study investigating CAR-T cell therapy for adjuvant treatment in solid tumors, specifically for pancreatic cancer (PC). Notably, on September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the innovative drug directory for commercial insurance. It is reported that all five CAR-T drugs, including CARSGEN-B's Zewokilanse, passed expert review and are expected to be included in this year's basic medical insurance directory and the commercial insurance innovative drug directory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1101078272","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101078272","pubTimestamp":1760926094,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) experienced a surge of over 9% in early trading, reaching a gain of 9.49% to HKD 17.66, with a trading volume of HKD 11.95 million. The company announced that the research results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B"},"translate_title":"港股异动|科济源-B(02171)早盘大涨超9%，公司在ESMO 2025上展示泽沃基兰注射液研究","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"CARSGEN-B (02171) experienced a surge of over 9% in early trading, reaching a gain of 9.49% to HKD 17.66, with a trading volume of HKD 11.95 million. The company announced that the research results for Zewokilanse injection (Product ID: CT053), an autologous CAR-T cell product targeting BCMA, were presented in a poster session at the 2025 European Society for Medical Oncology (ESMO) annual meeting. This clinical trial represents the world's first proof-of-concept study investigating CAR-T cell therapy for adjuvant treatment in solid tumors, specifically for pancreatic cancer (PC). Notably, on September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the innovative drug directory for commercial insurance. It is reported that all five CAR-T drugs, including CARSGEN-B's Zewokilanse, passed expert review and are expected to be included in this year's basic medical insurance directory and the commercial insurance innovative drug directory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}